BRIEF-GSK files with FDA for Promacta sNDA

Fri Feb 28, 2014 9:53am EST

Related Topics

Feb 28 (Reuters) - GlaxoSmithKline Plc : * Press release: GSK announces submission to U.S. regulatory authorities for

Promacta (eltrombopag) for severe aplastic anaemia * Announced today the submission of a supplemental new drug application (snda)

to the U.S. food and drug administration (fda) for Promacta * Application based on results from phase II nih study of eltrombopag in 43

heavily pre-treated saa patients *

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.